For example, ERBB2 amplification[26] and fibroblast growth factor receptor 1 gene (FGFR1) amplification[27] are drivers of therapeutic resistance and poor prognosis in ER+ breast cancer. This evidence concerns the gene ERBB2 and breast cancer.